Key result
BNT162b2 mRNA booster increases anti-spike antibodies ~130-fold in infection-naive nursing home residents.
Why the study?
Antibody levels and protection against SARS-CoV-2 have declined over time after initial vaccination in nursing home residents, prompting booster vaccination.
Does SARS-CoV-2 BNT162b2 mRNA booster vaccination improve humoral immune response in nursing home residents and health care workers?
Cohort (n=129)
Yes
Does SARS-CoV-2 BNT162b2 mRNA booster vaccination improve humoral immune response in nursing home residents and health care workers?
Effect estimate: GMFR 130 (95% CI 90, 188)
Absolute Event Rate: 1977% vs 15%
p-value: p=<0.001
BNT162b2 mRNA booster vaccination significantly increases antibody and neutralization titers in both nursing home residents and healthcare workers, supporting booster recommendations.
Booster linked to large antibody rises in residents; hypothesis-generating for protection, should not yet change practice.
Nursing home (NH) residents have experienced significant morbidity and mortality to SARS-CoV-2 throughout the pandemic. Vaccines initially curbed NH resident morbidity and mortality, but antibody levels and protection have declined with time since vaccination, prompting introduction of booster vaccination. This study assesses humoral immune response to booster vaccination in 85 NH residents and 44 health care workers (HCW) that we have followed longitudinally since initial SARS-CoV-2 BNT162b2 mRNA vaccination. The findings reveal that booster vaccination significantly increased anti-spike, anti-receptor binding domain, and neutralization titers above the pre-booster levels in almost all NH residents and HCW to significantly higher levels than shortly after the completion of the initial vaccine series. These data support the CDC recommendation to offer vaccine boosters to HCWs and NH residents on an immunological basis. Notably, even the older, more frail and more multi-morbid NH residents have sizable antibody increases with boosting.
No takes yet. Share an insight, caveat, or question.
Canaday et al. (2021) conducted a cohort in SARS-CoV-2 (n=129). SARS-CoV-2 BNT162b2 mRNA booster vaccination vs. Pre-booster levels was evaluated on Anti-spike antibody geometric mean fold rise (GMFR) from pre-booster to post-booster in infection-naive nursing home residents (GMFR 130, 95% CI 90, 188, p=<0.001). SARS-CoV-2 BNT162b2 mRNA booster vaccination significantly increased anti-spike antibody levels by a geometric mean fold rise of 130 in infection-naive nursing home residents compared to pre-booster levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: